This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
|Podcasts|August 18, 2010
Podcast:Clinical Formulations: Part of an Integrated Pharmaceutical Development and Manufacturing Platform
Advertisement
Clinical Formulations: Part of an Integrated Pharmaceutical Development and Manufacturing Platform
Event Overview:
Formulation Development is a key element in the pharmaceutical development process. There is an increasing trend by companies to outsource not just this service, but an integrated platform of pharmaceutical development and manufacturing capabilities, with the ultimate objective of accelerating their overall drug development program. This podcast details the benefits of outsourcing formulation development through a provider offering this type of integrated platform.
This episode discusses the increasing trend by companies to outsource formulation development to providers offering an integrated platform of pharmaceutical development and manufacturing capabilities.
Advertisement
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Advertisement
Advertisement